Aug 30 (Reuters) - Valbiotis SA ::CASH POSITION OF €3.9 MILLION AT 30 JUNE 2019.H1 NET LOSS EUR 2.7 MILLION VERSUS LOSS EUR 1.9 MILLION YEAR AGO.H1 OPERATING LOSS EUR 2.6 MILLION VERSUS LOSS EUR 1.9 MILLION YEAR AGO.H1 OPERATING REVENUE EUR 1.0 MILLION VERSUS EUR 0.5 MILLION YEAR AGO.WE APPROACH THE SECOND HALF OF THE YEAR WITH CONFIDENCE - CEO.
Full Article
Feb 11 (Reuters) - VALBIOTIS SAS ::VALBIOTIS OBTAINS THE EUROPEAN PATENT FOR VALEDIA®.GUARANTEED EXCLUSIVITY ON PREDIABETES AND METABOLIC DISEASES MARKET IN 38 COUNTRIES ACROSS EUROPE, INCLUDING EUROPEAN UNION.VALEDIA NOW HOLDS INDUSTRIAL PROPERTY RIGHTS FOR TWO MAJOR GLOBAL MARKETS: EUROPE AND UNITED STATES.THIS PATENT GUARANTEES EXCLUSIVE EXPLOITATION RIGHTS OF VALEDIA® UNTIL 2035 IN EUROPE, INCLUDING 28 COUNTRIES OF EUROPEAN UNION..TOTUM-63 PATENT IS CO-OWNED WITH CNRS (FRENCH NATIONAL CENTER FOR SCIENTIFIC RESEARCH).
Full Article
Valbiotis SAS ::VALBIOTIS INITIATES THE CLINICAL DEVELOPMENT OF VALEDIATM IN THE UNITED-STATES WITH THE REVERSE-IT CLINICAL STUDY.
Full Article
March 21 (Reuters) - VALBIOTIS SAS ::VALBIOTIS APPOINTS DR. CHRISTINE ROY-DUVAL AS DIRECTOR OF DEVELOPMENT AND MEDICAL AFFAIRS.
Full Article
Dec 4 (Reuters) - VALBIOTIS SAS ::ANNOUNCES FIRST PRECLINICAL DATA ON METFORMIN + TOTUM-63 COMBINATION FOR POSSIBLE USE IN DIABETES REAL LIFE PRACTICE.NO RISK OF HYPOGLYCEMIA FOR THE METFORMIN + TOTUM-63 COMBINATION SHOWN IN PRECLINICAL STUDIES.FIRST POSITIVE PRECLINICAL RESULTS ON INSULINEMIA, DURING AN ORAL GLUCOSE TOLERANCE TEST.GOOD INITIAL RESULTS PAVE WAY FOR CLINICAL TRIAL IN TYPE 2 DIABETIC PATIENTS TREATED WITH METFORMIN.
Full Article
Earnings vs. 
Estimates